Skip to content

Lucid Diagnostics LUCD Financing Cash Flow

Financing Cash Flow at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
-$5.03M-224%
Guardant Health logo
Guardant HealthGH
-$21.58M+67.7%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$16.9M+17,320%
Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
$24.7M-13.5%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$44.83M-301%
Personalis, Inc. logo
Personalis, Inc.PSNL
$17.83M-11.2%

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Gross margin-66.8%
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Reported directly by Lucid Diagnostics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's financing cash flow?
Lucid Diagnostics (LUCD) reported financing cash flow of $5.49M in Q1 2026.
How has Lucid Diagnostics's financing cash flow changed year-over-year?
Lucid Diagnostics's financing cash flow decreased by 64.5% year-over-year, from $15.44M to $5.49M.
What is the long-term trend for Lucid Diagnostics's financing cash flow?
Over 4 years (2021 to 2025), Lucid Diagnostics's financing cash flow has grown at a -4.9% compound annual growth rate (CAGR), from $72.08M to $59.03M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.